
A new drug targeting a hormone linked to hypertension has shown encouraging results in patients with chronic kidney disease.
A drug that showed early signs of protecting damaged kidneys has now received FDA approval for treating high blood pressure that remains uncontrolled despite medication. Called Baxfendy (baxdrostat), the treatment targets a hormone involved in both hypertension and kidney disease.
The approval follows Phase 3 clinical trials showing substantial blood pressure reductions. Earlier research also found that baxdrostat lowered a key marker of kidney damage by 55%, suggesting potential benefits beyond hypertension. Whether the medication can slow kidney disease progression remains under investigation.
FDA Approval Backed by Strong Clinical Trial Results
The FDA approved AstraZeneca’s Baxfendy in May 2026 for adults whose hypertension remains inadequately controlled by existing treatments. It is the first approved aldosterone synthase inhibitor, a class of drugs that reduces production of the hormone aldosterone.
In the Phase 3 BaxHTN trial involving 796 patients, the 2 mg dose reduced systolic blood pressure by an average of 15.7 mm Hg after 12 weeks, compared with 5.8 mm Hg for placebo. The additional reduction of 9.8 mm Hg was statistically significant. A lower 1 mg dose also produced meaningful improvements.
Dr. Bryan Williams, Chair of Medicine at University College London and the trial’s primary investigator, said: “We have been waiting for an innovative medication like Baxfendy for hypertension for many years. Its novel way of lowering blood pressure has the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension. In addition, the nearly double-digit placebo-adjusted systolic blood pressure reduction achieved with Baxfendy is exciting and clinically meaningful for clinicians and patients. Epidemiological data indicate that a 10 mmHg decrease in systolic blood pressure is associated with a roughly 20% lower risk of serious cardiovascular events.”
How the Drug Targets a Major Cause of Hypertension
Aldosterone regulates sodium and water balance in the body. Excessive levels cause the kidneys to retain fluid, increasing blood pressure and potentially contributing to kidney inflammation and scarring.
Baxdrostat inhibits the enzyme responsible for producing aldosterone rather than blocking the hormone’s receptors, as some existing medications do. This approach may benefit patients whose blood pressure remains high despite multiple treatments.
A separate Phase 3 trial, Bax24, involving 218 patients found that baxdrostat lowered average systolic blood pressure over 24 hours by 14.0 mm Hg more than placebo. The effect persisted throughout the day and night, according to findings published in The Lancet.
Earlier Study Finds Potential Kidney Benefits
High blood pressure and chronic kidney disease can worsen each other. Elevated pressure damages the kidneys’ filtering structures, while declining kidney function makes hypertension harder to control.
“These findings are encouraging for people living with chronic kidney disease and high blood pressure, two conditions that often go hand-in-hand and create a dangerous cycle,” said lead study author Jamie P. Dwyer, M.D., a professor of medicine at University of Utah Health. “High blood pressure can worsen kidney function and declining kidney function can further elevate blood pressure, and these outcomes can be life-altering for patients.”
In the Phase 2 FigHTN trial, 192 patients with chronic kidney disease and uncontrolled hypertension were randomly assigned to receive baxdrostat or placebo alongside standard treatment. After 26 weeks, systolic blood pressure fell an average of 8.1 mm Hg more in the baxdrostat groups.
Researchers also measured urinary albumin, a protein associated with kidney damage when present in elevated amounts. Levels were 55% lower in patients receiving baxdrostat than in those taking placebo. The findings were published in the Journal of the American Society of Nephrology.
Safety Concerns and Remaining Questions
The earlier kidney disease trial found elevated blood potassium in 41% of baxdrostat recipients, compared with 5% of placebo recipients. Most cases were mild or moderate, but excessive potassium can cause dangerous heart rhythm disturbances. Serious adverse events occurred in 9% and 3% of participants, respectively.
Although subsequent Phase 3 hypertension studies reported no unexpected safety findings, potassium levels and kidney function require monitoring during treatment.
“The reduction in urine albumin gives us hope that baxdrostat may also help delay kidney damage. This potential is now being tested in two large Phase 3 trials to determine if baxdrostat delays the progression of kidney disease,” said Dwyer.
Larger studies are investigating whether baxdrostat can preserve kidney function over time, including trials combining it with dapagliflozin, an established kidney-protective medication. Its FDA approval currently covers hypertension, not the prevention of kidney disease progression.
“These new findings are reassuring that this new class of antihypertensive medications are likely to have both kidney- and cardio-protective benefits and to be safe and effective for broad patient populations,” said Jordana B. Cohen, M.D., M.S.C.E., immediate past chair of the American Heart Association’s Hypertension and Kidney Cardiovascular Science Committee. “Patients with chronic kidney disease were historically often excluded from drug studies. It is particularly reassuring to know that patients with chronic kidney disease, who have very high rates of hypertension and elevated renin-angiotensin aldosterone activity, were represented in their own study, tolerated the medication well, and had both blood pressure and albuminuric benefits. This medication class could be a game changer in the management of hypertension in this patient group.”
References:
“Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial” by Jamie P. Dwyer, Noha Maklad, Ola Vedin, John Monyak, Robin Myte, Glenn M. Chertow, Hiddo J.L. Heerspink and Dustin J. Little, 6 September 2025, Journal of the American Society of Nephrology.
DOI: 10.1681/ASN.0000000849
DOI: 10.1016/S0140-6736(25)02549-8
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.